Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

8    GlaxoSmithKline    $14.2B    down 6.6%
Global revenue: $43.4B (7th); down 3.6%

R&D spend: $5.9B (7th), down 3.3%; 13.6% of rev.

Top brands: Advair ($4.6B), Lovaza ($899M), Flovent ($709M), Avodart ($525M), Vesicare ($199M)

Planned launches: Relovair (asthma); 444+719   (COPD); GSK1349572 (HIV/AIDS)

Promotional spend: $1.0B (5th); 7.3% of rev.

Patent expirations: Diskus device (2013-25); Avodart (2015), Lovaza (2017)

Despite three new vaccine approvals and a 12% return on R&D investment, GlaxoSmithKline continues to tread rough waters. The number eight pharmaceutical company has seen vaccine and pharmaceutical sales shrink 31% between 2009 and 2011, partly due to patent expirations. The company exhibits a dogged commitment to plan: despite a US government push to vaccinate boys against HPV, the company said girls and women will remain the target group for vaccine Cervarix, yielding the field to Merck's Gardasil; a generic of top seller Advair could launch soon; and the company has also given ground in the OTC market, including selling 17 brands to Prestige Brand Holdings, although it's having trouble unloading weight-loss drug Alli.

Back to first page

Page 8 of 21
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters